http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Kunnumakkara Ajaikumar B. (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Curcumin, Inflammation, and Neurological disorders: How are they linked?
Garodia Prachi,Hegde Mangala,Kunnumakkara Ajaikumar B.,Aggarwal Bharat B. 한국한의학연구원 2023 Integrative Medicine Research Vol.12 No.3
Background : Despite the extensive research in recent years, the current treatment modalities for neurological disorders are suboptimal. Curcumin, a polyphenol majorly found in Curcuma genus, has been shown to mitigate the pathophysiology and clinical sequalae involved in neuroinflammation and neurodegenerative diseases. Methods : We searched PubMed database for relevant publications on curcumin and its uses in treating neurological diseases. We also reviewed relevant clinical trials which appeared on searching PubMed database using ‘Curcumin and clinical trials’. Results : This review details the pleiotropic immunomodulatory functions and neuroprotective properties of curcumin, its derivatives and formulations in various preclinical and clinical investigations. The effects of curcumin on neurodegenerative diseases such as Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), brain tumors, epilepsy, Huntington's disorder (HD), ischemia, Parkinson's disease (PD), multiple sclerosis, and traumatic brain injury (TBI) with a major focus on associated signalling pathways have been thoroughly discussed. Conclusion : This review demonstrates curcumin can suppress spinal neuroinflammation by modulating diverse astroglia mediated cascades, ensuring the treatment of devastating neurological disorders.
-
Augustine Amalraj,Karthik Varma,Joby Jacob,Chandradhara Divya,Ajaikumar B. Kunnumakkara,Sidney J. Stohs,Sreeraj Gopi 한국식품영양과학회 2017 Journal of medicinal food Vol.20 No.10
Rheumatoid arthritis (RA) is an autoimmune, chronic systemic inflammatory disorder. The long-term use of currently available drugs for the treatment of RA has many potential side effects. Natural phytonutrients may serve as alternative strategies for the safe and effective treatment of RA, and curcuminoids have been used in Ayurvedic medicine for the treatment of inflammatory conditions for centuries. In this study, a novel, highly bioavailable form of curcumin in a completely natural turmeric matrix was evaluated for its ability to improve the clinical symptoms of RA. A randomized, double-blind, placebo-controlled, three-arm, parallel-group study was conducted to evaluate the comparative efficacy of two different doses of curcumin with that of a placebo in active RA patients. Twelve patients in each group received placebo, 250 or 500 mg of the curcumin product twice daily for 90 days. The responses of the patients were assessed using the American College of Rheumatology (ACR) response, visual analog scale (VAS), C-reactive protein (CRP), Disease Activity Score 28 (DAS28), erythrocyte sedimentation rate (ESR), and rheumatoid factor (RF) values. RA patients who received the curcumin product at both low and high doses reported statistically significant changes in their clinical symptoms at the end of the study. These observations were confirmed by significant changes in ESR, CPR, and RF values in patients receiving the study product compared to baseline and placebo. The results indicate that this novel curcumin in a turmeric matrix acts as an analgesic and anti-inflammatory agent for the management of RA at a dose as low as 250 mg twice daily as evidenced by significant improvement in the ESR, CRP, VAS, RF, DAS28, and ACR responses compared to placebo. Both doses of the study product were well tolerated and without side effects.
-
Elina Khatoon,Mangala Hegde,Aviral Kumar,Uzini Devi Daimary,Gautam Sethi,Anupam Bishyaee,Ajaikumar B. Kunnumakkara 대한약학회 2022 Archives of Pharmacal Research Vol.45 No.8
Oral cancer is one of the leading causes of cancer-related deaths, and it has become a matter of seriousconcern due to the alarming rise in its incidence rate worldwide. Despite recent advancements in oral cancer treatmentstrategies, there are no signifi cant improvements in patient’ssurvival rate. Among the numerous cell signaling pathwaysinvolved in oral cancer development and progression, STAT3is known to play a multifaceted oncogenic role in shapingthe tumor pathophysiology. STAT3 hyperactivation in oralcancer contributes to survival, proliferation, invasion, epithelialto mesenchymal transition, metastasis, immunosuppression,chemoresistance, and poor prognosis. A plethoraof pre-clinical and clinical studies have documented the roleof STAT3 in the initiation and development of oral cancer and showed that STAT3 inhibition holds signifi cant potentialin the prevention and treatment of this cancer. However, todate, targeting STAT3 activation mainly involves inhibitingthe upstream signaling molecules such as JAK and IL-6receptors. The major challenge in targeting STAT3 lies inthe complexity of its phosphorylation- and dimerizationindependentfunctions, which are not aff ected by disruptingthe upstream regulators. The present review delineates thesignifi cance of the STAT3 pathway in regulating varioushallmarks of oral cancer. In addition, it highlights the STAT3inhibitors identifi ed to date through various preclinical andclinical studies that can be employed for the therapeuticintervention in oral cancer treatment.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
